Emalex Biosciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Holding

Established: 2018-01-01

Employees: 11

Market Cap: -

Website: http://www.emalexbiosciences.com

Clinical Trials

Food-effect Study of Ecopipam Pharmacokinetics

Phase 1

Completed

Conditions: Food-effect

Interventions: Drug: Ecopipam tablet

First Posted Date: 2024-11-01

Last Posted Date: 2025-01-27

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 25

Registration Number: NCT06669091

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

Drug Interaction Study

Phase 1

Completed

Conditions: Drug Interaction

Interventions: Drug: Itraconazole
Drug: rifampicin
Drug: Ecopipam

First Posted Date: 2024-01-08

Last Posted Date: 2024-08-28

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 45

Registration Number: NCT06194864

Locations: 🇨🇦
Syneos Health Clinic Inc., Québec, Quebec, Canada

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Phase 3

Recruiting

Conditions: Tourette Syndrome

Interventions: Drug: Ecopipam

First Posted Date: 2023-09-01

Last Posted Date: 2025-04-22

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 150

Registration Number: NCT06021522

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Josephson-Wallack-Munshower Neurology, Indianapolis, Indiana, United States
🇺🇸
University of Louisville Research Foundation Inc., Louisville, Kentucky, United States

and more 63 locations

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

Phase 1

Completed

Conditions: QT/QTc

Interventions: Drug: Placebo
Drug: Ecopipam Hydrochloride
Drug: Moxifloxacin

First Posted Date: 2023-05-03

Last Posted Date: 2023-06-09

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 29

Registration Number: NCT05841160

Locations: 🇺🇸
PPD Austin Phase 1 Clinical Research Unit, Austin, Texas, United States

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Phase 3

Completed

Conditions: Tourette Disorder

Interventions: Drug: Ecopipam Hydrochloride

First Posted Date: 2022-11-14

Last Posted Date: 2025-04-30

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 216

Registration Number: NCT05615220

Locations: 🇩🇰
Borne og Ungeafdelingen, Herlev, Denmark
🇫🇷
CHU Grenoble Alpes - Hopital Couple Enfant, Grenoble, France
🇫🇷
Hôpital Fondation Rothschild, Paris, France

and more 92 locations

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

Phase 1

Completed

Conditions: Drug Interaction

Interventions: Drug: Ecopipam
Combination Product: Cohort 1 Probe Substrate Cocktail
Combination Product: Cohort 3 Probe Substrate Cocktail
Drug: Cohort 2 Probe Substrate

First Posted Date: 2022-04-19

Last Posted Date: 2022-12-12

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 56

Registration Number: NCT05334108

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Phase 1

Completed

Conditions: Drug Interaction

Interventions: Drug: ecopipam HCL
Drug: Divalproex Sodium ER
Drug: Mefenamic acid

First Posted Date: 2021-05-26

Last Posted Date: 2021-07-22

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 38

Registration Number: NCT04902105

Locations: 🇺🇸
Syneos Health Clinical Research Services, LLC., Miami, Florida, United States

Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: [14C]-Ecopipam

First Posted Date: 2021-05-11

Last Posted Date: 2021-12-03

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 8

Registration Number: NCT04881955

Locations: 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Phase 1

Terminated

Conditions: Drug-Interactions

Interventions: Drug: ecopipam HCl ~2mg/kg/day
Combination Product: Cohort 1 Probe Cocktail
Combination Product: Cohort 2 Probe Cocktail
Combination Product: Cohort 3 Probe Cocktail

First Posted Date: 2021-02-21

Last Posted Date: 2021-05-24

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 30

Registration Number: NCT04764851

Locations: 🇺🇸
Syneos Health Clinical Research Services, LLC., Miami, Florida, United States

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

Phase 2

Completed

Conditions: Childhood-Onset Fluency Disorder (Stuttering)

Interventions: Drug: Placebo
Drug: Ecopipam

First Posted Date: 2020-07-30

Last Posted Date: 2022-04-28

Lead Sponsor: Emalex Biosciences Inc.

Target Recruit Count: 68

Registration Number: NCT04492956

Locations: 🇺🇸
Clinical Neuroscience Solutions Inc, Memphis, Tennessee, United States
🇺🇸
UC Riverside, Riverside, California, United States
🇺🇸
Michigan State University, East Lansing, Michigan, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy